In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis ...
Overall survival (OS) data, published simultaneously by the Journal of Clinical Oncology, 2 show the longest survival data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback